Skip to content

tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients

Transcranial Random Noise Stimulation in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01876524
Acronym
tRND&SUDs
Enrollment
225
Registered
2013-06-12
Start date
2013-07-01
Completion date
2014-09-01
Last updated
2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Disorder With Hyperactivity, Bipolar Disorder, Personality Disorder, Schizophrenia, Substance Use Disorder

Keywords

Substance Use Disorder, Attention Deficit Disorder With Hyperactivity, Schizophrenia, Bipolar disorder, Personality disorder

Brief summary

The purpose of this study is to study the efficacy and security of noninvasive brain stimulation as a new approach for patients with Substance Use Disorders (SUDs) plus other psychiatric conditions like ADHD, Schizophrenia, Bipolar disorder, etc.

Detailed description

Background: There is an intimate relationship between addictive behaviors and other mental disorders, proven by clinical practice and many epidemiological studies, genetic and neuroscience. This gives risk to the diagnosis of Dual Pathology: an addiction and another mental disorder. Functional neuroimaging studies have shown that anterior cingulate cortex is associated with substance´s dependence and craving. Transcranial random noise stimulation (tRNS) stimulates parts of the brain and can change it´s activity. Researchers are interested in reduce cravings for substance dependence on patients with Dual Pathology using tRNS in anterior cingulate cortex. Aims: To determine whether tRNS in anterior cingulate cortex can reduce craving over Dual Pathology patients.

Interventions

Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas

Sponsors

Spanish Foundation for Neurometrics Development
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* \> 18 years old and less than 60 years * Best-practice diagnosed Dual Pathology * Diagnosed since at least two years prior to enrollment. * Abuse more than 2 Substances ExclusionC riteria: * Serious visual and hearing loss * Brain injury following cranial trauma * Other neurological disorders like Parkinson, ME, headache, etc. * Birth trauma * Mental retardation * Pregnant

Design outcomes

Primary

MeasureTime frameDescription
AMEN QuestionnarieFollowing patients during 3 months after Brain noninvasive estimulation100 Items Questionnarie subdivided in 5 subscales: basal ganglia, cingulate cortez, temporal cortex, prefrontal cortex and limbic system
Emotional Visual Event Related PotentialsFollowing patients during 3 months after Brain noninvasive estimulationEmotional Visual Event Related Potentials responses (time courses and topographies) and ICA components related with them, identified by Mitsar 201M EEG Amplifier using EEGLab software \[ Time Frame: brainwaves patterns following an array of visual stimuli (human faces) during a 22 min. examination \]

Secondary

MeasureTime frameDescription
CAGE Adapted to Include Drugs (CAGE-AID)Following 3 months after tRNS brain stimulationThe CAGE-AID is a sensitive screen for alcohol and drug problems.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026